Pharma BD Deal Intelligence
Sanofi acquired Bioverativ for $11.6B for hemophilia treatment.
Sanofi announced the successful completion of its acquisition of Bioverativ Inc. for $105 per share in cash, strengthening its position in the hemophilia…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Sanofi acquired Bioverativ for $11.6B for hemophilia treatment.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Bioverativ Inc. (this deal) | 2018 | $11.6B | 56 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2018 deals · Sanofi SA deals · Hematology deals